Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate

Autores
Zuazo, Rocío; Bazán Bouyrie, Ana Julia; Vitti, Agustín Daniel; Morelli, María Paula; Martin, Candela; Santos, Javier; Musella, Rosa; Palmero, Juan Domingo; Calamante, Gabriela; Del Medico Zajac, Maria Paula; Amiano, Nicolás Oscar; García, Verónica Edith
Año de publicación
2026
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.
Instituto de Biotecnología
Fil: Zuazo, Rocío. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Bazán Bouyrie, Ana Julia. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Vitti, Agustín Daniel. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Morelli, María Paula. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Martin, Candela. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Biociencias, Biotecnología y Biología Traslacional (iB3); Argentina
Fil: Musella, Rosa María. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; Argentina
Fil: Palmero, Domingo Juan. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; Argentina
Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Del Médico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Orgánica; Argentina
Fil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fuente
International Journal of Molecular Sciences 27 (17) : 7827 (September 2026)
Materia
Tuberculosis
Vacuna
Mycobacterium tuberculosis
Vaccines
Antigens
Antigenos
Rv2626c
Inmunogenicidad
Immunogenicity
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
INTA Digital (INTA)
Institución
Instituto Nacional de Tecnología Agropecuaria
OAI Identificador
oai:localhost:20.500.12123/27889
Acceder
id INTADig_aa79144521ca43f6027fc6efa3031ecf
oai_identifier_str oai:localhost:20.500.12123/27889
network_acronym_str INTADig
repository_id_str l
network_name_str INTA Digital (INTA)
spelling Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine CandidateZuazo, RocíoBazán Bouyrie, Ana JuliaVitti, Agustín DanielMorelli, María PaulaMartin, CandelaSantos, JavierMusella, RosaPalmero, Juan DomingoCalamante, GabrielaDel Medico Zajac, Maria PaulaAmiano, Nicolás OscarGarcía, Verónica EdithTuberculosisVacunaMycobacterium tuberculosisVaccinesAntigensAntigenosRv2626cInmunogenicidadImmunogenicityAn estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.Instituto de BiotecnologíaFil: Zuazo, Rocío. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: Bazán Bouyrie, Ana Julia. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; ArgentinaFil: Vitti, Agustín Daniel. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: Morelli, María Paula. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: Martin, Candela. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; ArgentinaFil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Biociencias, Biotecnología y Biología Traslacional (iB3); ArgentinaFil: Musella, Rosa María. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; ArgentinaFil: Palmero, Domingo Juan. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; ArgentinaFil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Del Médico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; ArgentinaFil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Orgánica; ArgentinaFil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; ArgentinaFil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; ArgentinaMDPI2026-09-22T14:05:25Z2026-09-22T14:05:25Z2026-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/27889https://www.mdpi.com/1422-0067/27/17/78271422-0067https://doi.org/10.3390/ijms27177827International Journal of Molecular Sciences 27 (17) : 7827 (September 2026)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2026-09-24T11:43:52Zoai:localhost:20.500.12123/27889instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2026-09-24 11:43:52.716INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse
dc.title.none.fl_str_mv Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
title Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
spellingShingle Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
Zuazo, Rocío
Tuberculosis
Vacuna
Mycobacterium tuberculosis
Vaccines
Antigens
Antigenos
Rv2626c
Inmunogenicidad
Immunogenicity
title_short Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
title_full Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
title_fullStr Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
title_full_unstemmed Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
title_sort Targeting Latent Tuberculosis: Immunogenic Evaluation of a Mycobacterium tuberculosis Dormancy Antigen as a Vaccine Candidate
dc.creator.none.fl_str_mv Zuazo, Rocío
Bazán Bouyrie, Ana Julia
Vitti, Agustín Daniel
Morelli, María Paula
Martin, Candela
Santos, Javier
Musella, Rosa
Palmero, Juan Domingo
Calamante, Gabriela
Del Medico Zajac, Maria Paula
Amiano, Nicolás Oscar
García, Verónica Edith
author Zuazo, Rocío
author_facet Zuazo, Rocío
Bazán Bouyrie, Ana Julia
Vitti, Agustín Daniel
Morelli, María Paula
Martin, Candela
Santos, Javier
Musella, Rosa
Palmero, Juan Domingo
Calamante, Gabriela
Del Medico Zajac, Maria Paula
Amiano, Nicolás Oscar
García, Verónica Edith
author_role author
author2 Bazán Bouyrie, Ana Julia
Vitti, Agustín Daniel
Morelli, María Paula
Martin, Candela
Santos, Javier
Musella, Rosa
Palmero, Juan Domingo
Calamante, Gabriela
Del Medico Zajac, Maria Paula
Amiano, Nicolás Oscar
García, Verónica Edith
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Tuberculosis
Vacuna
Mycobacterium tuberculosis
Vaccines
Antigens
Antigenos
Rv2626c
Inmunogenicidad
Immunogenicity
topic Tuberculosis
Vacuna
Mycobacterium tuberculosis
Vaccines
Antigens
Antigenos
Rv2626c
Inmunogenicidad
Immunogenicity
dc.description.none.fl_txt_mv An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.
Instituto de Biotecnología
Fil: Zuazo, Rocío. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Bazán Bouyrie, Ana Julia. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Vitti, Agustín Daniel. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Morelli, María Paula. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Martin, Candela. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
Fil: Santos, Javier. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Biociencias, Biotecnología y Biología Traslacional (iB3); Argentina
Fil: Musella, Rosa María. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; Argentina
Fil: Palmero, Domingo Juan. Ciudad Autónoma de Buenos Aires. Hospital Muñiz. División Tisioneumonología; Argentina
Fil: Calamante, Gabriela. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Del Médico Zajac, Maria Paula. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Agrobiotecnología y Biología Molecular; Argentina
Fil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: Amiano, Nicolás Oscar. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Orgánica; Argentina
Fil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Instituto de Química Biológica; Argentina
Fil: García, Verónica Edith. Universidad de Buenos Aires. Facultad de Ciencias Exactas y Naturales. Departamento de Química Biológica; Argentina
description An estimated 2.1 billion people are infected with Mycobacterium tuberculosis (Mtb) and at risk of developing active tuberculosis (TB). Because Mtb exists in replicating and dormant states, effective vaccines should target antigens from both stages. Here, we evaluated the immunogenicity and vaccine potential of Mtb dormancy antigen Rv2626c. Cellular and humoral immune responses were studied in individuals with latent TB infection (LTBI), active TB, and healthy donors (HD) using flow cytometry and ELISA. Overlapping peptides spanning Rv2626c sequence and structural mapping were employed to characterize Rv2626c immunogenic regions. Additionally, the protective efficacy of a Modified Vaccinia Ankara (MVA) vector expressing Rv2626c was evaluated in a murine challenge model. Rv2626c induced cellular immunity selectively in LTBI, characterized by increased frequencies of CD4+IFN-γ+, SLAMF1+, and poly-functional T lymphocytes. Immunodominant peptide regions were identified across the protein sequence. Moreover, mice immunized with MVA-Rv2626c showed a significant reduction in splenic bacterial burden following a challenge with Mtb H37Rv. Altogether, our findings indicate that the latency-associated antigen Rv2626c elicits immune responses in LTBI subjects and limits bacterial dissemination in our mice model of infection. Therefore, Rv2626c arises as a promising candidate to be combined with active phase antigens in multistage vaccines against Mtb infection.
publishDate 2026
dc.date.none.fl_str_mv 2026-09-22T14:05:25Z
2026-09-22T14:05:25Z
2026-09
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/20.500.12123/27889
https://www.mdpi.com/1422-0067/27/17/7827
1422-0067
https://doi.org/10.3390/ijms27177827
url http://hdl.handle.net/20.500.12123/27889
https://www.mdpi.com/1422-0067/27/17/7827
https://doi.org/10.3390/ijms27177827
identifier_str_mv 1422-0067
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv International Journal of Molecular Sciences 27 (17) : 7827 (September 2026)
reponame:INTA Digital (INTA)
instname:Instituto Nacional de Tecnología Agropecuaria
reponame_str INTA Digital (INTA)
collection INTA Digital (INTA)
instname_str Instituto Nacional de Tecnología Agropecuaria
repository.name.fl_str_mv INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria
repository.mail.fl_str_mv tripaldi.nicolas@inta.gob.ar
_version_ 1877227359196676096
score 13.265058

Publicaciones similares